First Parkinson’s Patients Treated in Landmark Phase 2 Trial of Dapansutrile, Expanding a Leading Oral NLRP3 Inhibitor into Neurological Diseases

March 24, 2026 – Olatec Therapeutics, Inc. (“Olatec”) developing one of the most clinically advanced specific oral NLRP3 inhibitors, dapansutrile, today announced that two patients have been randomized in a 12-month clinical trial, named DAPA-PD, for the treatment of Parkinson’s disease (PD). This milestone launches dapansutrile into Phase 2 clinical development for neurological conditions, expanding upon ongoing trials with dapansutrile in rheumatologic diseases (Phase 2/3 gout), oncology (Phase 2 advanced melanoma), and cardiometabolic disorders (Phase 2 type 2 diabetes). As a specific oral NLRP3 inhibitor, dapansutrile targets the core inflammatory mechanism shown to fuel disease progression across numerous age-related rheumatologic, oncologic, cardiometabolic, and neurologic disorders. Dapansutrile offers potential for disease modification as monotherapy or as a complement to existing treatments by directly addressing the shared pathological inflammatory driver in these conditions. Developing dapansutrile across multiple inflammation-based diseases is supported by its remarkably favorable safety and tolerability profile observed across preclinical studies and clinical trials in diverse disease populations, positioning it as a highly promising chronic therapy with wide therapeutic use. The DAPA-PD trial is a single-center randomized, double-blind, placebo-controlled study being conducted at Cambridge University Hospitals NHS Foundation Trust/University of Cambridge under principal investigator, Dr. Caroline Williams-Gray, BMBCh, FRCP, PhD, and funded by Cure Parkinson’s and Van Andel Institute through the International Linked Clinical Trials program... Jan 20 Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's Studies​ New York, NY

The release as fetched from its publisher. olatec.com ↗